Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC drugs of abuse test labeling with SAMHSA drug standards urged at public hearing.

This article was originally published in The Tan Sheet

Executive Summary

OTC DRUGS OF ABUSE TEST LABELING WITH SAMHSA LIMITATIONS SUGGESTED by Benjamin Gerson, MD, American Society of Clinical Pathologists, at a June 19 public hearing to solicit public comment on FDA's proposed rule to downclassify collection devices for OTC drugs of abuse tests from Class III to Class I. Labeling should "clearly and explicitly" state what drugs the system will and will not test based on the standards of the Substance Abuse & Mental Health Services Administration, Gerson said.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088594

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel